Immunovant, Inc. (IMVT)

(A Top Pick Feb 16/21, Down 18.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with IMVT has triggered our recommended stop at $15. To be disciplined, we recommend covering the position. We will look for better opportunities.

Stockchase Research Editor: Michael O'Reilly IMVT is an emerging biotech company that develops treatment for autoimmune diseases, such as thyroid eye disease. Their products can be disruptive as they offer far less invasive treatments to products on the market today. The company is awaiting approval of its products, so it is not generating revenue currently making this a more speculative recommendation. We would buy this with a stop-loss at $15. This TOP PICK has substantial upside potential, so we will set an initial upside target of $35 (over 55% upside) to assess its further opportunity. Yield 0%. (Analysts’ price target is $44.75)